Ignite Creation Date:
2025-12-25 @ 12:04 AM
Ignite Modification Date:
2026-02-26 @ 2:14 AM
Study NCT ID:
NCT02114658
Status:
COMPLETED
Last Update Posted:
2017-08-03
First Post:
2014-04-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D013964', 'term': 'Thyroid Neoplasms'}, {'id': 'D018276', 'term': 'Carcinoma, Medullary'}], 'ancestors': [{'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D013959', 'term': 'Thyroid Diseases'}, {'id': 'D018278', 'term': 'Carcinoma, Neuroendocrine'}, {'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D018299', 'term': 'Neoplasms, Ductal, Lobular, and Medullary'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077157', 'term': 'Sorafenib'}], 'ancestors': [{'id': 'D010671', 'term': 'Phenylurea Compounds'}, {'id': 'D014508', 'term': 'Urea'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009536', 'term': 'Niacinamide'}, {'id': 'D009539', 'term': 'Nicotinic Acids'}, {'id': 'D000147', 'term': 'Acids, Heterocyclic'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 18}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-04-15', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-08', 'completionDateStruct': {'date': '2016-08-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-08-01', 'studyFirstSubmitDate': '2014-04-08', 'studyFirstSubmitQcDate': '2014-04-14', 'lastUpdatePostDateStruct': {'date': '2017-08-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2014-04-15', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-02-23', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability', 'timeFrame': '6 months'}, {'measure': 'Change in red blood cell count', 'timeFrame': 'Baseline and 6 months'}, {'measure': 'Change in white blood cell count', 'timeFrame': 'Baseline and 6 months'}, {'measure': 'Change in alanine aminotransaminase level (ALT)', 'timeFrame': 'Baseline and 6 months'}, {'measure': 'Change in aspartate aminotransferase level (AST)', 'timeFrame': 'Baseline and 6 months'}, {'measure': 'Change in blood pressure', 'timeFrame': 'Baseline and 6 months'}], 'secondaryOutcomes': [{'measure': 'Best overall response based on RECIST 1.1 criteria', 'timeFrame': 'Baseline and every 56 days up to progressive disease,an expected average of 8 months'}, {'measure': 'Plasma concentration of sorafenib', 'timeFrame': 'Cycle 2 Day 1'}, {'measure': 'Progression-free survival (PFS)', 'timeFrame': 'Baseline to progression or death by any reason'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Baseline to death by any reason'}, {'measure': 'Response rate (RR)', 'timeFrame': 'Baseline and every 56 days up to progressive disease', 'description': 'RR based on RECIST 1.1 criteria'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': 'Baseline and every 56 days up to progressive disease', 'description': 'DCR based on RECIST 1.1 criteria'}, {'measure': 'Maximum reduction from baseline in the target lesion size', 'timeFrame': 'Baseline and every 56 days up to progressive disease'}, {'measure': 'Maximum percentage change of calcitonin and Carcinoembryonic antigen (CEA) values from baseline', 'timeFrame': 'Baseline and every 56 days up to progressive disease', 'description': 'MTC subjects only'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Anaplastic and medullary thyroid carcinoma', 'Thyroid Neoplasms'], 'conditions': ['Thyroid Carcinoma']}, 'descriptionModule': {'briefSummary': 'The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Japanese patients with ATC (Anaplastic thyroid carcinoma) or locally advanced or metastatic MTC (medullary thyroid carcinoma)\n* Not a candidate for surgery or radiotherapy with curative intent\n* Histologically or cytologically confirmed ATC or MTC\n* Measurable or non-measurable disease (but clinically evaluable) according to RECIST 1.1.\n* Age \\>= 18 years\n* Adequate bone marrow, liver and renal function to be conducted within 14 days prior to treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1\n* Life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n* Histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma\n* Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies (licensed or investigational) that target VEGF or VEGF (vascular endothelial growth factor) receptors or other targeted agents\n* Prior chemotherapy for thyroid cancer (only one regimen is allowed)\n* Major surgery, open biopsy, or significant traumatic injury within 30 days prior to enrollment in the study.\n* Subjects with tracheal, bronchial or esophageal infiltration with significant risk of bleeding but without having received local treatment prior to enrollment in the study'}, 'identificationModule': {'nctId': 'NCT02114658', 'briefTitle': 'Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients', 'organization': {'class': 'INDUSTRY', 'fullName': 'Bayer'}, 'officialTitle': 'A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma', 'orgStudyIdInfo': {'id': '17073'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Arm 1', 'description': 'Sorafenib 400 mg bid continuous dose', 'interventionNames': ['Drug: Sorafenib (Nexavar,BAY43-9006)']}], 'interventions': [{'name': 'Sorafenib (Nexavar,BAY43-9006)', 'type': 'DRUG', 'description': 'Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle', 'armGroupLabels': ['Arm 1']}]}, 'contactsLocationsModule': {'locations': [{'zip': '650-0011', 'city': 'Kobe', 'state': 'Hyōgo', 'country': 'Japan', 'geoPoint': {'lat': 34.6913, 'lon': 135.183}}, {'zip': '390-8621', 'city': 'Matsumoto', 'state': 'Nagano', 'country': 'Japan', 'geoPoint': {'lat': 36.23333, 'lon': 137.96667}}, {'zip': '113-8603', 'city': 'Bunkyo-ku', 'state': 'Tokyo', 'country': 'Japan'}, {'zip': '135-8550', 'city': 'Koto-ku', 'state': 'Tokyo', 'country': 'Japan'}, {'zip': '545-8586', 'city': 'Osaka', 'country': 'Japan', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}], 'overallOfficials': [{'name': 'Bayer Study Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Bayer'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Bayer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}